REFERENCES
1. Lindman BR, Perry AS, Lance ML, et al. Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure. Nat Commun. 2025;16:6889.
2. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15:387-407.
3. Clavel M, Tastet L, Pibarot P. Cardiac remodelling in aortic stenosis. Arch Cardiovasc Dis. 2026;119:32-8.
4. Martini E, Cremonesi M, Felicetta A, et al. Autoimmune-like mechanism in heart failure enables preventive vaccine therapy. Circ Res. 2025;136:4-25.
5. Obst R, Van Santen H, Mathis D, Benoist C. Antigen persistence is required throughout the expansion phase of a CD4+ T cell response. J Exp Med. 2005;201:1555-65.
6. Wang H, Kwak D, Fassett J, et al. Role of bone marrow-derived CD11c+ dendritic cells in systolic overload-induced left ventricular inflammation, fibrosis and hypertrophy. Basic Res Cardiol. 2017;112:25.
7. Kologrivova I, Shtatolkina M, Suslova T, Ryabov V. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction. Front Immunol. 2021;12:664457.
8. Patel B, Ismahil MA, Hamid T, Bansal SS, Prabhu SD. Mononuclear phagocytes are dispensable for cardiac remodeling in established pressure-overload heart failure. PLoS ONE. 2017;12:e0170781.
9. Gröschel C, Sasse A, Monecke S, et al. CD8+-T cells with specificity for a model antigen in cardiomyocytes can become activated after transverse aortic constriction but do not accelerate progression to heart failure. Front Immunol. 2018;9:2665.
10. Suetomi T, Willeford A, Brand CS, et al. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+/calmodulin-dependent protein kinase II δ signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation. 2018;138:2530-44.
11. Ngwenyama N, Kirabo A, Aronovitz M, et al. Isolevuglandin-modified cardiac proteins drive CD4+ T-cell activation in the heart and promote cardiac dysfunction. Circulation. 2021;143:1242-55.
12. Guo Y, You Y, Shang F, et al. iNOS aggravates pressure overload-induced cardiac dysfunction via activation of the cytosolic-mtDNA-mediated cGAS-STING pathway. Theranostics. 2023;13:4229-46.
13. Martini E, Kunderfranco P, Peano C, et al. Single-cell sequencing of mouse heart immune infiltrate in pressure overload-driven heart failure reveals extent of immune activation. Circulation. 2019;140:2089-107.
14. Ngwenyama N, Salvador AM, Velázquez F, et al. CXCR3 regulates CD4+ T cell cardiotropism in pressure overload-induced cardiac dysfunction. JCI Insight. 2019;4:e125527.
15. Amrute JM, Luo X, Penna V, et al. Targeting immune-fibroblast cell communication in heart failure. Nature. 2024;635:423-33.
16. Saleh D, Jones RTL, Schroth SL, Thorp EB, Feinstein MJ. Emerging roles for dendritic cells in heart failure. Biomolecules. 2023;13:1535.
17. Liu X, Shi G, Guo J. Innate immune cells in pressure overload-induced cardiac hypertrophy and remodeling. Front Cell Dev Biol. 2021;9:659666.
18. Canton J, Blees H, Henry CM, et al. The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat Immunol. 2020;22:140-53.
19. Van Der Borght K, Scott CL, Martens L, et al. Myocarditis elicits dendritic cell and monocyte infiltration in the heart and self-antigen presentation by conventional type 2 dendritic cells. Front Immunol. 2018;9:2714.
20. Feng G, Bajpai G, Ma P, et al. CCL17 aggravates myocardial injury by suppressing recruitment of regulatory T cells. Circulation. 2022;145:765-82.
21. Blanton RM, Carrillo-Salinas FJ, Alcaide P. T-cell recruitment to the heart: friendly guests or unwelcome visitors? Am J Physiol Heart Circ Physiol. 2019;317:H124-40.
22. Lv H, Havari E, Pinto S, et al. Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans. J Clin Investig. 2011;121:1561-73.
23. Van Der Borght K, Scott CL, Nindl V, et al. Myocardial infarction primes autoreactive T cells through activation of dendritic cells. Cell Rep. 2017;18:3005-17.
24. Nevers T, Salvador AM, Grodecki-Pena A, et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail. 2015;8:776-87.
25. Gröschel C, Sasse A, Röhrborn C, et al. T helper cells with specificity for an antigen in cardiomyocytes promote pressure overload-induced progression from hypertrophy to heart failure. Sci Rep. 2017;7:15998.
26. Smolgovsky S, Bayer AL, Aronovitz M, et al. Experimental pressure overload induces a cardiac neoantigen specific humoral immune response. J Mol Cell Cardiol. 2025;201:87-93.
27. Heron C, Dumesnil A, Houssari M, et al. Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure. Cardiovasc Res. 2023;119:492-505.
28. Kallikourdis M, Martini E, Carullo P, et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun. 2017;8:14680.
29. Laroumanie F, Douin-Echinard V, Pozzo J, et al. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014;129:2111-24.
30. Smolgovsky S, Bayer AL, Kaur K, et al. Impaired T cell IRE1α/XBP1 signaling directs inflammation in experimental heart failure with preserved ejection fraction. J Clin Investig. 2023;133:e171874.
31. Williams C, Giovacchini D, Kennedy A, et al. CD28 and TCR differentially impact naïve and memory T cell responses. Discov Immunol. 2025;4:kyaf006.
32. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973-88.
33. Song EJ, Joachimbauer A, Tasca S, et al. T cells in acute and chronic myocarditis: from diagnosis to treatment. Eur Heart J. 2026;47:2255-70.
34. Tatsumi N, El-Fenej J, Davila-Pagan A, Kumamoto Y. CD301b+ dendritic cell-derived IL-2 dictates CD4+ T helper cell differentiation. Nat Commun. 2025;16:2002.
35. Inui H, Nishida M, Ichii M, et al. XCR1+ conventional dendritic cell-induced CD4+ T helper 1 cell activation exacerbates cardiac remodeling after ischemic myocardial injury. J Mol Cell Cardiol. 2023;176:68-83.
36. Bhattarai U, He X, Niu Z, et al. Pharmacological inhibition of IL12β is effective in treating pressure overload-induced cardiac inflammation and heart failure. Front Immunol. 2025;16:1624940.
37. Bhattarai U, He X, Xu R, et al. IL-12α deficiency attenuates pressure overload-induced cardiac inflammation, hypertrophy, dysfunction, and heart failure progression. Front Immunol. 2023;14:1105664.
38. Nevers T, Salvador AM, Velazquez F, et al. Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. J Exp Med. 2017;214:3311-29.
39. Bayer AL, Smolgovsky S, Ngwenyama N, et al. T-cell MyD88 is a novel regulator of cardiac fibrosis through modulation of T-cell activation. Circ Res. 2023;133:412-29.
40. Smolgovsky S, Theall B, Wagner N, Alcaide P. Fibroblasts and immune cells: at the crossroad of organ inflammation and fibrosis. Am J Physiol Heart Circ Physiol. 2024;326:H303-16.
41. Wang J, Duan Y, Sluijter JP, Xiao J. Lymphocytic subsets play distinct roles in heart diseases. Theranostics. 2019;9:4030-46.
42. Shang AQ, Yu CJ, Bi X, et al. Blocking CTLA‐4 promotes pressure overload‐induced heart failure via activating Th17 cells. FASEB J. 2024;38:e23851.
43. Wang H, Hou L, Kwak D, et al. Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression. Hypertension. 2016;68:114-22.
44. Souza-Neto F, Le P, Abdrabbo M, et al. CXCL10 regulates pressure overload-induced heart failure. JACC Basic Transl Sci. 2026;11:101462.
45. Sanders E, Alcaide P. Red light-green light: T-cell trafficking in cardiac and vascular inflammation. Am J Physiol Cell Physiol. 2023;324:C58-66.
46. Ngwenyama N, Kaur K, Bugg D, et al. Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction. Nat Cardiovasc Res. 2022;1:761-74.
47. Martín P, Sánchez-Madrid F. T cells in cardiac health and disease. J Clin Investig. 2025;135:e185218.
48. Linthout S, Matz I, González A, Davis J. Cardiac fibroblasts in myocardial injury and heart failure. Eur Heart J. 2026;47:2271-85.
49. Carrillo-Salinas FJ, Anastasiou M, Ngwenyama N, et al. Gut dysbiosis induced by cardiac pressure overload enhances adverse cardiac remodeling in a T cell-dependent manner. Gut Microbes. 2020;12:1823801.
50. Han Y, Li Y, Jia L, et al. Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in ang II-induced cardiac inflammation and fibrosis. PLoS ONE. 2012;7:e35506.
51. Chen X, Chen F, Jia S, Lu Q, Zhao M. Antigen-presenting fibroblasts: emerging players in immune modulation and therapeutic targets. Theranostics. 2025;15:3332-44.
52. Nishida K, Yamaguchi O, Hirotani S, et al. p38α mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol. 2023;24:10611-20.
53. Brassington K, Kanellakis P, Cao A, et al. Crosstalk between cytotoxic CD8+ T cells and stressed cardiomyocytes triggers development of interstitial cardiac fibrosis in hypertensive mouse hearts. Front Immunol. 2022;13:1040233.
54. Santos-Zas I, Lemarié J, Zlatanova I, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021;12:1483.
55. Lovell J, Duque C, Rousseau S, et al. B cell-mediated antigen presentation promotes adverse cardiac remodeling in chronic heart failure. Res Sq. 2024:rs.3.rs-4536350.
56. He X, Xu R, Pan L, et al. Inhibition of NK1.1 signaling attenuates pressure overload-induced heart failure, and consequent pulmonary inflammation and remodeling. Front Immunol. 2023;14:1215855.
57. Ritterhoff J, Tian R. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. Nat Rev Cardiol. 2023;20:812-29.
58. Nomura S, Satoh M, Fujita T, et al. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure. Nat Commun. 2018;9:4435.
59. Sattler S, Fairchild P, Watt FM, Rosenthal N, Harding SE. The adaptive immune response to cardiac injury—the true roadblock to effective regenerative therapies? NPJ Regen Med. 2017;2:19.
60. Ghigo A, Franco I, Morello F, Hirsch E. Myocyte signalling in leucocyte recruitment to the heart. Cardiovasc Res. 2014;102:270-80.
61. Halade GV, Lee DH. Inflammation and resolution signaling in cardiac repair and heart failure. eBioMedicine. 2022;79:103992.
62. Ninh VK, Brown JH. The contribution of the cardiomyocyte to tissue inflammation in cardiomyopathies. Curr Opin Physiol. 2021;19:129-34.
63. Salvador AM, Nevers T, Velázquez F, et al. Intercellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure. J Am Heart Assoc. 2016;5:e003126.
64. Tsuda T. Clinical assessment of ventricular wall stress in understanding compensatory hypertrophic response and maladaptive ventricular remodeling. J Cardiovasc Dev Dis. 2021;8:122.
65. Wang H, Kwak D, Fassett J, et al. CD28/B7 deficiency attenuates systolic overload-induced congestive heart failure, myocardial and pulmonary inflammation, and activated T cell accumulation in the heart and lungs. Hypertension. 2016;68:688-96.
66. Xing Y, Xie S, Shi W, Zeng X, Deng W, Tang Q. Targeting interleukin-21 inhibits stress overload-induced cardiac remodelling via the TIMP4/MMP9 signalling pathway. Eur J Pharmacol. 2023;940:175482.
67. Abe H, Tanada Y, Omiya S, et al. NF-κB activation in cardiac fibroblasts results in the recruitment of inflammatory Ly6Chi monocytes in pressure-overloaded hearts. Sci Signal. 2021;14:eabe4932.
68. Alexanian M, Padmanabhan A, Nishino T, et al. Chromatin remodelling drives immune cell-fibroblast communication in heart failure. Nature. 2024;635:434-43.
